Abstract

The nucleoprotein (NP) of Ebola virus (EBOV) and Marburg virus (MARV) is an essential component of the viral ribonucleoprotein complex and significantly impacts replication and transcription of the viral RNA genome. Although NP is regarded as a promising antiviral druggable target, no chemical ligands have been reported to interact with EBOV NP or MARV NP. We identified two compounds from a traditional Chinese medicine Gancao (licorice root) that can bind both NPs by combining affinity mass spectrometry and metabolomics approaches. These two ligands, 18β-glycyrrhetinic acid and licochalcone A, were verified by defined compound mixture screens and further characterized with individual ligand binding assays. Accompanying biophysical analyses demonstrate that binding of 18β-glycyrrhetinic acid to EBOV NP significantly reduces protein thermal stability, induces formation of large NP oligomers, and disrupts the critical association of viral ssRNA with NP complexes whereas the compound showed no such activity on MARV NP. Our study has revealed the substantial potential of new analytical techniques in ligand discovery from natural herb resources. In addition, identification of a chemical ligand that influences the oligomeric state and RNA-binding function of EBOV NP sheds new light on antiviral drug development.

Highlights

  • The prominent role of virus NPs as a valid target in antiviral drug development has been manifested in studies on influenza A virus (IAV) NP

  • The compound mixture dissociated from the NP complexes or the protein-free control was subjected to metabolomic analysis using liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS)

  • We applied multiple criteria to select putative ligands enriched in the Ebola virus (EBOV) NP or Marburg virus (MARV) NP complexes which include: 1) variable influence on projection (VIP) score > 1.0, representing compounds most implicated in the difference between the NP complex and control27,28; 2) average S/N value > 2.0 and RSD < 30%, indicating significant change of peak intensity of the compound in the protein complex relative to control19,20; 3) matching the accurate mass of a putative ligand to the traditional Chinese medicine (TCM) compound database for Chinese licorice

Read more

Summary

Introduction

The prominent role of virus NPs as a valid target in antiviral drug development has been manifested in studies on influenza A virus (IAV) NP. The only known ligand of EBOV NP is a peptide derived from the protein component VP35 within the viral nucleocapsid[11,12] This VP35 peptide binds NP with high affinity and specificity, inhibits NP oligomerization, and releases RNA from NP-RNA complexes in vitro. Previous elegant structural work on the VP35 peptide bound EBOV NP complex reveals how the peptide ligand occludes a large surface area important for NP assembly, NP-RNA interactions, and viral RNA synthesis[11,12]. These results strongly imply that EBOV NP can be a good target for therapeutic development. Our study has revealed the substantial potential of affinity MS coupled to metabolomic techniques in ligand discovery from natural herb resources for the development of small-molecule therapies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call